Cytokinetics (NASDAQ:CYTK) Director B Lynne Parshall Sells 5,000 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director B Lynne Parshall sold 5,000 shares of the stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $71.48, for a total value of $357,400.00. Following the sale, the director owned 10,784 shares of the company’s stock, valued at approximately $770,840.32. This represents a 31.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics Price Performance

Shares of CYTK stock opened at $71.40 on Wednesday. Cytokinetics, Incorporated has a 1-year low of $44.91 and a 1-year high of $88.31. The stock’s fifty day moving average price is $79.78 and its 200 day moving average price is $72.36. The company has a market cap of $8.88 billion, a price-to-earnings ratio of -9.89 and a beta of 0.36.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The business had revenue of $28.62 million during the quarter, compared to analysts’ expectations of $17.59 million. During the same quarter last year, the business posted ($1.12) earnings per share. The company’s quarterly revenue was down 57.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Cytokinetics, Incorporated will post -6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. Royal Bank Of Canada dropped their target price on shares of Cytokinetics from $117.00 to $112.00 and set an “outperform” rating on the stock in a research report on Friday, August 7th. Needham & Company LLC lifted their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Stifel Nicolaus boosted their price objective on shares of Cytokinetics from $98.00 to $108.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Citigroup reissued a “market outperform” rating on shares of Cytokinetics in a research report on Friday, August 7th. Finally, Wall Street Zen cut Cytokinetics from a “hold” rating to a “sell” rating in a research report on Saturday. Nineteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cytokinetics presently has an average rating of “Moderate Buy” and an average price target of $102.20.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reached a Phase 3 milestone in non-obstructive hypertrophic cardiomyopathy (HCM), highlighting progress in its cardiovascular pipeline and potentially expanding the opportunity for its muscle-directed therapies. Cytokinetics Reaches a Phase 3 First in Non-Obstructive HCM
• Positive Sentiment: The company presented new Phase 3 data, prompting continued discussion of the pipeline’s value; one analysis characterized CYTK as approximately 34% undervalued. Cytokinetics Presents New Phase 3 Data
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $140 price target, implying substantial upside from the stock’s recent level. The broader analyst consensus remains “Moderate Buy,” with a target near $102.20.
• Neutral Sentiment: Recent quarterly results exceeded expectations, with a loss of $1.50 per share versus the expected $1.63 loss and revenue of $28.62 million versus a $17.59 million estimate. However, revenue declined 57.1% year over year and the company remains unprofitable.
• Negative Sentiment: CEO Robert Blum sold 7,500 shares for approximately $526,800, EVP Andrew Callos sold 10,000 shares for about $702,400, and director B. Lynne Parshall sold 5,000 shares for roughly $357,400. All trades were conducted under pre-arranged Rule 10b5-1 plans, reducing their value as signals of current management sentiment, though the sales may still weigh modestly on investor confidence. Cytokinetics Insider Trading Activity
• Negative Sentiment: Wall Street Zen lowered its rating on CYTK, providing a counterpoint to the more optimistic sell-side outlook.

Institutional Trading of Cytokinetics

Several large investors have recently made changes to their positions in the business. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Cytokinetics during the second quarter worth $630,000. California State Teachers Retirement System boosted its holdings in Cytokinetics by 7,880.8% in the second quarter. California State Teachers Retirement System now owns 10,901,679 shares of the biopharmaceutical company’s stock valued at $928,714,000 after purchasing an additional 10,765,080 shares during the last quarter. AlphaGrep UK Ltd acquired a new stake in Cytokinetics during the 2nd quarter worth about $285,000. Seven Fleet Capital Management LP raised its stake in shares of Cytokinetics by 93.0% during the 2nd quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company’s stock valued at $10,073,000 after buying an additional 56,971 shares during the last quarter. Finally, Syon Capital LLC purchased a new position in shares of Cytokinetics during the 2nd quarter valued at about $228,000.

Cytokinetics Company Profile

Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.